For research use only. Not for therapeutic Use.
Gedivumab（Cat No.:I042090）is an investigational monoclonal antibody designed to target the immune checkpoint protein PD-1 (programmed cell death protein 1). By blocking PD-1, gedivumab aims to enhance the immune system’s ability to recognize and eliminate cancer cells. PD-1 plays a role in suppressing immune responses, particularly within the tumor microenvironment, allowing cancers to evade immune detection. Gedivumab is being studied in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma, to assess its safety, efficacy, and potential in combination with other immunotherapies to improve treatment outcomes.
| Catalog Number | I042090 |
| CAS Number | 1807954-17-1 |
| Purity | ≥95% |
